GENFIT announces the launch by Labcorp of NASHnext® a novel noninvasive diagnostic test powered by GENFIT’s NIS4™ technology to identify patients with at-risk NASH

LILLE, France; CAMBRIDGE, Mass., May 3, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the launch of NASHnext®, a novel, noninvasive diagnostic test for nonalcoholic steatohepatitis (NASH). The test is offered exclusively in the U.S. and Canada through Labcorp, a leading global life sciences company. NASHnext® is powered by NIS4™, GENFIT’s proprietary diagnostic technology that uses a novel, blood-based molecular biomarker test to identify NASH and significant fibrosis, also referred to as at-risk NASH, in patients with at least one metabolic risk factor, as published in The Lancet Gastroenterology and Hepatology.  

Labcorp announces proposed sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--May 12, 2021-- Labcorp (NYSE: LH) (“Labcorp”) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the “Notes”). 

Labcorp and the U.S. Department of Health and Human Services join forces to raise awareness of COVID-19 treatments

BURLINGTON, N.C. --(BUSINESS WIRE)--May 11, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, is working with the U.S. Department of Health and Human Services (HHS) to raise awareness of potentially lifesaving monoclonal antibody COVID-19 therapies.

Labcorp to acquire Myriad Autoimmune’s Vectra testing business from Myriad Genetics

BURLINGTON, N.C. --(BUSINESS WIRE)--May 3, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. More than one million Vectra tests have been completed since the product’s launch in November 2010, and a meaningful portion of testing volume currently flows through Labcorp.

OmniSeq receives New York state approval for OmniSeq INSIGHT genomic and immune profiling test

BUFFALO, N.Y., April 28, 2021 - OmniSeq®, an innovator in next generation sequencing in oncology, today announced the New York State Department of Health's Clinical Laboratory Evaluation Program has approved the OmniSeq INSIGHTSM  test. The test detects genomic variants, genomic signatures, and immune gene expression, providing physicians with clinically actionable evidence to inform therapeutic treatment decisions and identify potential clinical trial options for patients with late-stage solid tumor cancers.

Labcorp announces 2021 first quarter results

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 29, 2021-- Labcorp (NYSE: LH), a leading life sciences company, today announced results for the first quarter ended March 31, 2021 and raised 2021 guidance.